Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States

Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States

Tracey Weiss,1 Richard D Carr,2,3 Sampriti Pal,4 Lingfeng Yang,1 Baanie Sawhney,4 Robert Boggs,1 Swapnil Rajpathak,1 Kristy Iglay1 1Center for Observational and Real-World Evidence, Merck & Co., Inc, Kenilworth, NJ, 07033, USA; 2Global Medical Affairs, Merck Sharp & Dohme Limited (MS...

Full description

Bibliographic Details
Main Authors: Weiss T, Carr RD, Pal S, Yang L, Sawhney B, Boggs R, Rajpathak S, Iglay K
Format: Article
Language:English
Published: Dove Medical Press 2020-11-01
Series:Patient Preference and Adherence
Subjects:
glp-1 ra
adherence
discontinuation
united states
Online Access:https://www.dovepress.com/real-world-adherence-and-discontinuation-of-glucagon-like-peptide-1-re-peer-reviewed-article-PPA

Internet

https://www.dovepress.com/real-world-adherence-and-discontinuation-of-glucagon-like-peptide-1-re-peer-reviewed-article-PPA

Similar Items